Lilly gets FDA nod for Taltz to treat Plaque Psoriasis in children
Eli Lilly and Company (Lilly) has obtained the US Food and Drug Administration (FDA) approval for its Taltz (ixekizumab) to treat a type of plaque psoriasis in paediatric
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XEli Lilly and Company (Lilly) has obtained the US Food and Drug Administration (FDA) approval for its Taltz (ixekizumab) to treat a type of plaque psoriasis in paediatric
AstraZeneca has secured US FDA approval for its Imfinzi (durvalumab) to treat a type of extensive-stage small cell lung cancer (ES-SCLC). The US regulatory agency has approved the
Luminex has secured the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its NxTAG CoV Extended Panel, a diagnostic test intended for the detection of the
Abbott has secured the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its advanced molecular test to rapidly detect novel coronavirus (COVID-19). The new molecular
US-based Thermo Fisher Scientific has obtained the CE mark approval for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19, in the European
Swiss pharmaceutical firm Novartis has partnered with a consortium of life sciences companies to speed-up the development, manufacture and delivery of vaccines, diagnostics, and treatments for Coronavirus disease
Two teams of Italian researchers working on infectious diseases have analysed the SARS-CoV-2 genome using a new next-generation sequencing (NGS) research assay developed by Thermo Fisher Scientific. The
BrightInsight, a provider of Internet of Things (IoT) platform for biopharma and medtech, has entered into a global digital health partnership with biopharmaceutical firm AstraZeneca. As part of
Genentech, a Roche company, has secured the US Food and Drug Administration (FDA) approval for Phase 3 clinical trial intravenous Actemra (tocilizumab) plus standard of care in hospitalised
US-based healthcare technology firm Thermo Fisher Scientific will invest more than $475m in 2020 to enhance its new biologics, cell and gene therapies and drug products capabilities. The